ArticleCureus2025
Patterns, Risks, and Clinical Challenges of Pregabalin Misuse in Patients With Opioid Use Disorder: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregabalin, a gabapentinoid used for neuropathic pain and epilepsy, is increasingly misused, particularly among individuals with opioid use disorder (OUD). Its synergistic effects with opioids enhance euphoric sensation. Pregabalin misuse in OUD patients is driven by this enhanced euphoria and self-medication to control opioid withdrawal symptoms, and pregabalin is used as an opioid substitution. This increases the risk of respiratory depression and leads to severe withdrawal symptoms. This case series presents three individuals with comorbid OUD and high-dose pregabalin dependence, detailing their withdrawal symptoms, co-occurring substance use, and treatment intervention. Stricter regulations, prescriber awareness, and harm reduction strategies are essential to prevent such misuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.